Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Sexually Transmitted Diseases

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 61 articles: HTML format

Single Articles

September 2025
1. LEVY B, Schwarz N, Magen Z, Vaknin Z, et al
   Comment addressing the 2025 Zero Draft: A global call for HPV elimination.
   Int J Cancer. 2025 Sep 20. doi: 10.1002/ijc.70174.
   PubMed    
   
   
   
2. KOESTLER AJ, Nelson CW, Yeager M, Chen Z, et al
   Whole-genome sequencing of 1,083 HPV45 cases and controls identifies genetic variants associated with glandular cervical lesions.
   Int J Cancer. 2025;157:1130-1141.
   PubMed     Abstract available
   
   
   
3. TOTA JE, Shing JZ, Roberts JN, Anderson EM, et al
   Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era.
   Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70119.
   PubMed     Abstract available
   
   
   
4. ANDERSEN K, Bonde J, Waldstrom M, Jakobsen MV, et al
   Evaluation of targeted next-generation sequencing for detection of HPV genotypes and sublineages in cervical liquid-based cytology SurePath samples from the Danish screening program.
   Int J Cancer. 2025 Sep 11. doi: 10.1002/ijc.70148.
   PubMed     Abstract available
   
   
   
5. LIU H, Zou Z, Zhang L
   Reply to 'Comments on "HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis"'.
   Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70129.
   PubMed    
   
   
   
6. LIU Z, Tong X
   Comments on "HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis".
   Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70130.
   PubMed    
   
   
   August 2025
7. HAAS CB, Ocampo R, Liu D, Zuniga M, et al
   Design and initial findings of a natural history study of anal HPV and associated lesions among young adult women in Costa Rica.
   Int J Cancer. 2025 Aug 15. doi: 10.1002/ijc.70082.
   PubMed     Abstract available
   
   
   
8. NASMAN A, Birgersson M, Nasman T, Jortso E, et al
   Age and tumour presentations differ between HPV type 16 positive and other high-risk HPV type-positive oropharyngeal squamous cell carcinomas in a Swedish cohort of 2000-2022.
   Int J Cancer. 2025 Aug 15. doi: 10.1002/ijc.70087.
   PubMed     Abstract available
   
   
   July 2025
9. BJORGE T, Stoer NC, Hverven SK, Nygard M, et al
   Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study.
   Int J Cancer. 2025;157:251-259.
   PubMed     Abstract available
   
   
   June 2025
10. JENKINS M, Saidu R, Boa R, Mbatani N, et al
    Performance of thermoablation among women treated for high-risk human papillomavirus in a screen-and-treat program in South Africa.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35519.
    PubMed     Abstract available
    
    
    May 2025
11. KJAER SK, Frederiksen K, Rasmussen CL, Thomsen LT, et al
    Prognostic impact of p16 and high-risk HPV DNA in ~1300 patients with vulvar cancer.
    Int J Cancer. 2025 May 30. doi: 10.1002/ijc.35501.
    PubMed     Abstract available
    
    
    
12. DAMGAARD R, Jenkins D, Stoler MH, van de Sandt M, et al
    p16(INK4a) and HPV E4 immunohistochemistry for the prediction of regression of cervical intraepithelial neoplasia grade 2-A historical cohort study.
    Int J Cancer. 2025 May 5. doi: 10.1002/ijc.35469.
    PubMed     Abstract available
    
    
    April 2025
13. WEI Y, Gu L, Zhang Y, Yang Q, et al
    Efficacy of ALA-PDT in treating cervical low-grade squamous intraepithelial lesions with high-risk HPV patients: A multicentre randomized controlled trial.
    Int J Cancer. 2025 Apr 23. doi: 10.1002/ijc.35450.
    PubMed     Abstract available
    
    
    February 2025
14. KEBEDE HB, Mekuria S, Asegid N, Forslund O, et al
    High-risk human papillomavirus genotypes in previously unscreened reproductive-age women in Ethiopia: A community-based cohort study.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35335.
    PubMed     Abstract available
    
    
    
15. LEHTINEN M, van Damme P, Beddows S, Pinto LA, et al
    Scientific approaches to defining HPV vaccine-induced protective immunity.
    Int J Cancer. 2025 Feb 13. doi: 10.1002/ijc.35345.
    PubMed     Abstract available
    
    
    
16. RUNELLO F, Jary A, Duin S, Kim Y, et al
    DNA methylation and copy number alterations in the progression of HPV-associated high-grade vulvar intraepithelial lesion.
    Int J Cancer. 2025 Feb 12. doi: 10.1002/ijc.35366.
    PubMed     Abstract available
    
    
    
17. HARPER DM, Paczos T, Ridder R, Huh WK, et al
    p16/ki-67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions.
    Int J Cancer. 2025 Feb 4. doi: 10.1002/ijc.35353.
    PubMed     Abstract available
    
    
    
18. JIN F, Poynten IM, Hillman RJ, Law C, et al
    Does use of anal cytology as a triage test improve the performance of high-risk human papillomavirus screening in gay and bisexual men for anal cancer prevention?
    Int J Cancer. 2025;156:575-586.
    PubMed     Abstract available
    
    
    December 2024
19. VERHOEF L, Bleeker MCG, Polman N, Kroon KR, et al
    Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35289.
    PubMed     Abstract available
    
    
    
20. JHAWAR SR, Haring C, Pan X, Ma J, et al
    Impact of circulating tumor human papillomavirus DNA kinetics on disease outcomes in HPV-associated oropharyngeal cancer.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35291.
    PubMed     Abstract available
    
    
    
21. TUNG HJ, Wang YC, Lin CY, Liao MJ, et al
    Human papillomavirus prevalence, genotype distribution, and prognostic factors of vaginal cancer.
    Int J Cancer. 2024;155:1996-2008.
    PubMed     Abstract available
    
    
    November 2024
22. PEDERSEN BT, Sonne SB, Pedersen H, Andreasen EK, et al
    Participation and relative cost of attendance by direct-mail compared to opt-in invitation strategy for HPV self-sampling targeting cervical screening non-attenders: A large-scale, randomized, pragmatic study.
    Int J Cancer. 2024 Nov 23. doi: 10.1002/ijc.35263.
    PubMed     Abstract available
    
    
    
23. LIU H, Zou M, Shen M, Kamarulzaman A, et al
    HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.
    Int J Cancer. 2024 Nov 17. doi: 10.1002/ijc.35242.
    PubMed     Abstract available
    
    
    
24. KARIMI A, Mohebbi E, Mckay-Chopin S, Hadji M, et al
    Association of opium use and tobacco smoking with alpha-, beta-, and gamma-human papillomavirus oral infection.
    Int J Cancer. 2024;155:1544-1548.
    PubMed     Abstract available
    
    
    
25. LOUVANTO K, Verhoef L, Pimenoff V, Eriksson T, et al
    Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions.
    Int J Cancer. 2024;155:1549-1557.
    PubMed     Abstract available
    
    
    October 2024
26. MISHRA GA, Pimple SA, Anand KV, Kulkarni VY, et al
    Acceptability and validity of HPV self-sampling for cervical cancer screening among women living in different ecological settings in India.
    Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35222.
    PubMed     Abstract available
    
    
    September 2024
27. DEBEAUDRAP P, Kabore FN, Setha L, Tegbe J, et al
    Performance of visual inspection, partial genotyping, and their combination for the triage of women living with HIV who are screen positive for human papillomavirus: Results from the AIMA-CC ANRS 12375 multicentric screening study.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35190.
    PubMed     Abstract available
    
    
    
28. OSTRBENK VALENCAK A, Kroon KR, Fabjan D, Mlakar J, et al
    Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.
    Int J Cancer. 2024 Sep 24. doi: 10.1002/ijc.35200.
    PubMed     Abstract available
    
    
    
29. JERJES W
    Comments on "Epidemiological trends and survival of oropharyngeal cancer in a high HPV-prevalent area: A Danish population-based study from 2000 to 2020".
    Int J Cancer. 2024 Sep 6. doi: 10.1002/ijc.35178.
    PubMed    
    
    
    
30. VON BUCHWALD C, Lauritzen BB, Carlander AF, Jakobsen KK, et al
    Response to: Comments on "Epidemiological trends and survival of oropharyngeal cancer in a high HPV-prevalent area: A Danish population-based study from 2000 to 2020".
    Int J Cancer. 2024 Sep 6. doi: 10.1002/ijc.35177.
    PubMed    
    
    
    
31. FUJITA M, Nagashima K, Shimazu M, Suzuki M, et al
    Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
    Int J Cancer. 2024;155:905-915.
    PubMed     Abstract available
    
    
    July 2024
32. LAURITZEN BB, Gronlund MW, Jakobsen KK, Justesen MM, et al
    Epidemiological trends and survival of oropharyngeal cancer in a high HPV-prevalent area: A Danish population-based study from 2000 to 2020.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35099.
    PubMed     Abstract available
    
    
    
33. GILHAM C, Nedjai B, Scibior-Bentkowska D, Reuter C, et al
    Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
    Int J Cancer. 2024;155:81-92.
    PubMed     Abstract available
    
    
    May 2024
34. HANSEN BT, Nygard M, Castle PE, Burger EA, et al
    Sociodemographic characteristics associated with cervical cancer screening participation by send-to-all and opt-in HPV self-sampling: Who benefits? Results from a randomized controlled trial among long-term non-attending women in Norway.
    Int J Cancer. 2024 May 15. doi: 10.1002/ijc.34989.
    PubMed     Abstract available
    
    
    April 2024
35. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
    Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
    PubMed     Abstract available
    
    
    
36. SINGINI MG, Muchengeti M, Sitas F, Chen WC, et al
    Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34919.
    PubMed     Abstract available
    
    
    March 2024
37. PORTNOY A, Pedersen K, Sy S, Trope A, et al
    Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Int J Cancer. 2024;154:1073-1081.
    PubMed     Abstract available
    
    
    
38. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
    The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
    PubMed     Abstract available
    
    
    
39. LU Y, Clifford GM, Fairley CK, Grulich AE, et al
    Human papillomavirus and p16(INK4a) in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.
    Int J Cancer. 2024;154:830-841.
    PubMed     Abstract available
    
    
    February 2024
40. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
    The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
    PubMed     Abstract available
    
    
    
41. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
    Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
    Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
    PubMed     Abstract available
    
    
    January 2024
42. STIER EA, Clarke MA, Deshmukh AA, Wentzensen N, et al
    International Anal Neoplasia Society's consensus guidelines for anal cancer screening.
    Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34850.
    PubMed     Abstract available
    
    
    November 2023
43. 
    Correction to "A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers".
    Int J Cancer. 2023 Nov 19. doi: 10.1002/ijc.34789.
    PubMed    
    
    
    
44. BONI SP, Tenet V, Horo A, Heideman DAM, et al
    High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020.
    Int J Cancer. 2023 Nov 9. doi: 10.1002/ijc.34774.
    PubMed     Abstract available
    
    
    October 2023
45. COCUZZA CE, Dhillon SK, Martinelli M, Giubbi C, et al
    Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34754.
    PubMed     Abstract available
    
    
    September 2023
46. INTURRISI F, de Sanjose S, Desai KT, Dagnall C, et al
    A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
    Int J Cancer. 2023 Sep 29. doi: 10.1002/ijc.34698.
    PubMed     Abstract available
    
    
    
47. LEHTINEN M, Butt J, Gray P, Brenner N, et al
    HPV16 E6-antibody associated risk of oropharyngeal cancer increases by calendar-time: A nested case-control study.
    Int J Cancer. 2023;153:1313-1315.
    PubMed    
    
    
    
48. KUSTERS JMA, Diergaarde B, Ness A, Schim van der Loeff MF, et al
    Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex.
    Int J Cancer. 2023 Sep 11. doi: 10.1002/ijc.34710.
    PubMed     Abstract available
    
    
    
49. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available
    
    
    August 2023
50. WHITE C, Reynolds S, Murphy K, Keegan H, et al
    Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
    Int J Cancer. 2023 Aug 26. doi: 10.1002/ijc.34685.
    PubMed     Abstract available
    
    
    
51. VOSS FO, Thuijs NB, Duin S, Ozer M, et al
    Clinical validation of methylation biomarkers for optimal detection of high-grade vulvar intraepithelial neoplasia.
    Int J Cancer. 2023;153:783-791.
    PubMed     Abstract available
    
    
    July 2023
52. KIM MN, Han K, Yoo J, Hwang SG, et al
    Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
    Int J Cancer. 2023 Jul 13. doi: 10.1002/ijc.34637.
    PubMed     Abstract available
    
    
    
53. CLARKE MA, Wentzensen N
    Response to comments on: "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 Jul 4. doi: 10.1002/ijc.34642.
    PubMed    
    
    
    
54. DIAS GONCALVES LIMA F, Schim van der Loeff M
    Comments on: "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 Jul 4. doi: 10.1002/ijc.34641.
    PubMed    
    
    
    
55. REBOLJ M, Sargent A, Njor SH, Cuschieri K, et al
    Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly.
    Int J Cancer. 2023;153:8-19.
    PubMed     Abstract available
    
    
    May 2023
56. 
    Erratum to "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 May 19. doi: 10.1002/ijc.34567.
    PubMed    
    
    
    March 2023
57. CUZICK J, Adcock R, Kinney W, Castle PE, et al
    Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States.
    Int J Cancer. 2023 Mar 22. doi: 10.1002/ijc.34519.
    PubMed     Abstract available
    
    
    
58. DE SOUZA MMA, Hartel G, Olsen CM, Whiteman DC, et al
    Oral HPV infection and HPV vaccination in an Australian cohort.
    Int J Cancer. 2023 Mar 21. doi: 10.1002/ijc.34517.
    PubMed     Abstract available
    
    
    
59. ALBUQUERQUE A
    Comments on "Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis": Prevention of anal squamous cell carcinoma in women: How to move forward: Prevention of anal squamous c
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34490.
    PubMed    
    
    
    
60. DONG L, Nygard M, Stoer NC, Klungsoyr O, et al
    Real-World Effectiveness of Hpv Vaccination Against Cervical Neoplasia Among Birth Cohorts Ineligible for Routine Vaccination.
    Int J Cancer. 2023 Mar 3. doi: 10.1002/ijc.34489.
    PubMed     Abstract available
    
    
    January 2023
61. CARVAJAL LJ, Shing JZ, Vanegas JC, Gonzalez E, et al
    TRENDS IN INCIDENCE RATES OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS OVERALL AND BY POTENTIAL RELATEDNESS TO HUMAN PAPILLOMAVIRUS, COSTA RICA 2006-2015.
    Int J Cancer. 2023 Jan 17. doi: 10.1002/ijc.34437.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge.